Cetuximab is a recombinant monoclonal antibody that has been applied for various cancer treatments for many years. Biosimilar candidates for cancer therapies development is of great significance for humans. Based on first-in-class technology platforms, Creative Biolabs has made great achievements in glycoprotein investigations. We are proud to provide high-quality services in N-glycan profiling of biosimilar candidates at the most competitive cost.
Therapeutic recombinant monoclonal antibody (mAbs) drugs have emerged as a clinically important drug class, which were mainly used for cancer treatment. There are more than 30 therapeutic antibodies have been approved for clinical use. Cetuximab, a therapeutic mAb drug approved by FDA in 2009, actually is an epidermal growth factor receptor inhibitor that has been applied for clinical treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer, and head and neck cancer. Recent years, studies on biosimilar candidate are increasing. The development of biosimilar candidates of cetuximab is becoming a trend mainly due to:
Therefore, N-glycan profiling analysis of the mAbs or biosimilar candidate is becoming an increasingly critical process in antibody characterization and regulatory evaluation. Creative Biolabs has accumulated extensive experience in N-glycan profiling based on powerful technologies.
Fig.1 Strategy used in the new glycan analysis of antibodies (Yang, 2016).
Creative Biolabs has successfully developed several effective strategies in comprehensive N-glycan profiling of biosimilar candidates. If you need a professional scientific research staff and a full range of services on N-glycan profiling, just feel free to contact us for more detailed information.